← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일

현재 선택: 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV22행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCPhase 3
Bexarotene (Bexarotene)
Millennium Pharmaceuticals, Inc.·Primary Cutaneous Anaplastic Large…
ORR 54.7%·t½ 7 h
Overview
Program
Bexarotene
Overview
Company
Millennium Pharmaceuticals, Inc.
Overview
Modality
ADC
Overview
Target
Primary Cutaneous Anaplastic Large Cell
Overview
Indication
Primary Cutaneous Anaplastic Large Cell Lymphoma; Mycosis Fungoides
Overview
Phase
PHASE_3
Overview
Status
ACTIVE
MoA
Mechanism
targeted interventions and supports APOE-associated pathway
MoA
Biomarker
biomarker, and proposes novel therapeutic strategies integrating machine learning and deep learning approache
PK/PD
Half-life
7 h
PK/PD
Species
Mouse
PK/PD
Animal (cat.)
Mouse
PK/PD
Experiment
pd
Toxicology
Species
Mouse
Toxicology
Animal (cat.)
Mouse
Toxicology
Major finding
Vitamins and the skin: Vitamin A and retinoids in dermatology.. Vitamin A and analogs are widely used in dermatology, with retinoids being natural and synthetic vitamin A derivatives. Topical retinoids (especially tretinoin and tretinoin precursors) can diminish photoaging and contribute to the thickening and restoration of skin collagen. Retinoids used as therapeutic agents include oral retinoids…
Clinical
Primary efficacy
ORR 54.7%
Clinical
ORR
54.7%
Clinical
Result source
ClinicalTrials.gov NCT01578499
Clinical
Data Tier / Score
A · 56
Clinical
Program phase
PHASE_3
Clinical
Clinical sync
2026년 7월 13일 (1일 전)